|

PD-1 inhibitior Clinical Trials

2 actively recruiting trials

Pipeline

Phase 2: 2

Top Sponsors

  • Tianjin Medical University Second Hospital1
  • Mabwell (Shanghai) Bioscience Co., Ltd.1

Indications

  • Cancer2
  • Ureteral Cancer1
  • Kidney-sparing1
  • Tislelizumab1
  • Nab-paclitaxel1

Other2 trials

A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer
Phase 2
Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.